Counting the cost of public and philanthropic R & amp;D funding: the case of olaparib

ConclusionsGovernment or charitable funding of pharmaceutical product development is difficult to trace using publicly available sources, due to incomplete information provided by authors and/or a lack of consistency in funding information made available by funders. This study has shown that a Freedom of Information request, in countries where such requests are supported, can provide information to help build the picture of financial support. In the example of olaparib, the funding amounts directly reported considerably exceeded amounts that could be ascertained using publically available bibliographic sources.
Source: Journal of Pharmaceutical Policy and Practice - Category: Pharmaceuticals Source Type: research